Search
Regeneron Pharmaceuticals announced on Monday that it has secured the acquisition of nearly all assets of the bankrupt genetic testing firm, 23andMe Holding, through a bankruptcy auction for $256 million. This acquisition encompasses 23andMe's personal genomics services, its comprehensive health and research service business lines, along with its biobank and associated assets. Regeneron has committed to adhering to 23andMe's privacy policies and relevant legal frameworks, and will present its data utilization plans to the court-appointed monitor. The transaction is anticipated to conclude in the third quarter of 2025, at which time 23andMe will become a fully-owned subsidiary of Regeneron, continuing to offer personal genomics services. Notably, 23andMe's Lemonaid Health business is excluded from Regeneron's acquisition.
-
C114 Communication Network -
Communication Home
